Get the Stockscreener App
0.277
4.48%
-0.013
After Hours:
.29
0.013
+4.69%
Biorestorative Therapies Inc stock is traded at $0.277, with a volume of 676.77K.
It is down -4.48% in the last 24 hours and down -25.05% over the past month.
BioRestorative Therapies Inc is engaged in developing therapeutic products using cell and tissue protocols, involving adult stem cells. The company is pursuing its Disc/Spine Program with initial investigational therapeutic product being called BRTX-100 in the treatment of chronic cervical discogenic pain. The technology is an stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. It is also developing ThermoStem Program, a pre-clinical program which involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies.
See More
Previous Close:
$0.29
Open:
$0.29
24h Volume:
676.77K
Relative Volume:
0.07
Market Cap:
$7.06M
Revenue:
$357.90K
Net Income/Loss:
$-11.06M
P/E Ratio:
-0.2473
EPS:
-1.1201
Net Cash Flow:
$-11.90M
1W Performance:
-13.98%
1M Performance:
-25.05%
6M Performance:
-74.82%
1Y Performance:
-82.90%
1-Day Range:
$0.2698
$0.3124
1-Week Range:
$0.2698
$0.346
52-Week Range:
$0.1593
$1.89
Biorestorative Therapies Inc Stock (BRTX) Company Profile
Name
Biorestorative Therapies Inc
Sector
Industry
Phone
(631) 760-8100
Address
40 MARCUS DRIVE, MELVILLE
Compare BRTX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRTX
Biorestorative Therapies Inc
|
0.277 | 7.39M | 357.90K | -11.06M | -11.90M | -1.1201 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Biorestorative Therapies Inc Stock (BRTX) Latest News
BioRestorative Therapies Inc (BRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BioRestorative Therapies Inc (BRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BRTX|BioRestorative Therapies Inc|Price:0.290|Chg%:-0.022 - TradingKey
TradingKey - TradingKey
BioRestorative Therapies Inc (BRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioRestorative Therapies, Inc. Revenue Breakdown – GETTEX:9OF - TradingView
Biorestorative Therapies Company Profile & Introduction - Moomoo
BioRestorative Therapies Inc (BRTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BioRestorative Therapies (BRTX) Q1 2026 Earnings: Narrower Loss Beats Estimates as Company Advances PipelineAnnual Financial Report - dars.gov.et
BioRestorative Therapies Announces Amendments to Executive Employment Agreements in July 2026 - Minichart
Leadership shake-up at Biorestorative Therapies (NASDAQ: BRTX) and new CEO - Stock Titan
BioRestorative Therapies, Inc. Announces CFO Changes, Effective July 13, 2026 - marketscreener.com
BioRestorative Therapies (BRTX) Bounces from Support, Stages 3.5% RecoveryOBV Divergence - dars.gov.et
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
Kaos Capital Announces Acquisition of 4.9% Stake in BioRestorative Therapies (NASDAQ: BRTX) - AOL.com
Price to book forward of BioRestorative Therapies, Inc. – GETTEX:9OF - TradingView
BioRestorative Therapies (BRTX) Slides 1% to $0.40, Tests Key Support Amid Low VolumeWyckoff Upthrust - dars.gov.et
BRTX Q1 2026 Earnings: Narrower-than-Expected Loss Highlights Cost Discipline Amid Clinical Progress - dars.gov.et
Here's why Biorestorative Therapies (BRTX) looks ripe for bottom fishing - MSN
BioRestorative Therapies, Inc.'s Equity Buyback announced on August 12, 2025, has expired. - marketscreener.com
BioRestorative Therapies (BRTX) Rises 1.62% as Stock Holds Above Key Support at $0.36Volatility Stop - DonanımHaber
Enterprise value to EBITDA forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView
Price to earnings forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView
Price to earnings forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView
BioRestorative (NASDAQ:BRTX) Gains Penny Stock Attention - Kalkine Media
Enterprise value to revenue forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView
Enterprise value to revenue forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView
Price to book forward of BioRestorative Therapies, Inc. – NASDAQ:BRTX - TradingView
Price to sales forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView
Price to book forward of BioRestorative Therapies, Inc. – TRADEGATE:9OF - TradingView
BioRestorative Therapies, Inc. Actuals & Estimates (NASDAQ:BRTX) - TradingView
BRTX Forecast — Price Target — Prediction for 2027 - TradingView
BioRestorative Therapies, Inc. Actuals & Estimates (DUS:9OF) - TradingView
9OF Forecast — Price Target — Prediction for 2027 - TradingView
A3C9XF Forecast — Price Target — Prediction for 2027 - TradingView
BioRestorative Therapies Announces Completion of BRTX-100 Manufacturing for Phase 2 Clinical Trial - Moomoo
BioRestorative finishes BRTX-100 Phase 2 supply in-house - Stock Titan
BioRestorative Therapies Inc (BRTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
BRTX Q1 2026 Earnings: Narrowed Loss Per Share Beats Estimates, Stock RisesEarnings Analysis - dars.gov.et
BRTX News | BIORESTORATIVE THERAPIES INC (NASDAQ:BRTX) - ChartMill
Director Mika Grasso files initial Form 3 at BioRestorative (BRTX) - Stock Titan
BioRestorative Therapies (NASDAQ: BRTX) director Dhaliwal files clean Form 3 - Stock Titan
BioRestorative Therapies Inc (BRTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
BioRestorative Therapies Strengthens Leadership with Appointment of Healthcare Executive Zachary Smith as Vice President of Biocosmeceuticals Division to Accelerate Commercial Expansion and Strategic Growth - The Manila Times
BioRestorative Therapies Appoints Zachary Smith as Vice President of Biocosmeceuticals Division - Quiver Quantitative
BioRestorative Therapies Inc (BRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
BioRestorative Therapies Inc (BRTX) Institutional Confidence - TradingKey
BioRestorative Therapies (BRTX) director Katharyn Field files initial Form 3 - Stock Titan
BioRestorative Therapies Inc - TradingKey
Discontinued operations of BioRestorative Therapies, Inc. – DUS:9OF - TradingView
Long term debt to total equity ratio of BioRestorative Therapies, Inc. – DUS:9OF - TradingView
Biorestorative Therapies Inc Stock (BRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):